NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its first quarter revenues rose 9 percent thanks in large part to a 39 percent increase in system revenues and record revenues from assays and royalties.
For the three months ended March 31, the molecular diagnostics firm reported revenues of $63.0 million, up from $57.7 million a year ago, and beating the consensus Wall Street estimate of $61.0 million.